Latest Industry Insights

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

Developing and manufacturing biotherapeutics at scale requires thorough analysis of the active substance’s characteristics to ensure it fulfils both efficacy and safety requirements. Analytical technologies, such as mass spectrometry, are key tools adopted in this process.

Despite hydrogen being used successfully in many labs, concerns persist about converting existing helium-based methods to hydrogen. We speak to Aaron Boice from Agilent to learn how a new technology is helping with this transition.

In this interview, we spoke to Rachel Marty Pyke PhD, manager of bioinformatics science at Personalis, to find out how machine learning can be used to detect genomic instability as a biomarker for cancer immunotherapy.

The science and medicine worlds are experiencing a new revolution, and this time the protagonist is the mRNA molecule. In this article, we explore why bioplatforms support this revolution.

PerkinElmer announced the launch of a new automated gas chromatography, the GC 2400 Platform. We spoke to Suneet Chadha to learn more about this latest introduction.

Technology Networks spoke to Francisco Bizouarn, market development manager of the Digital Biology Group at Bio-Rad Laboratories, to find out how wastewater testing works and how it can anticipate a rise in cases of COVID-19 and the emergence of new variants.

In this interview, Lei Zhou, PhD, head of the Ocular Proteomics Platform at the Singapore Eye Research Institute, talks about the development of a novel diagnostic test to guide precision medicine to prevent dry eye in patients after laser eye surgery.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

We spoke to Geoff Winkett and Michel van den Berge from Agilent, about the concerns they hear from their customers in the pharmaceutical and biopharmaceutical sector and how they are helping to address them.